Relay Therapeutics (RLAY) to Release Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the business posted ($0.81) earnings per share. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Stock Down 0.5 %

Shares of RLAY traded down $0.03 during midday trading on Thursday, hitting $5.68. The company's stock had a trading volume of 707,995 shares, compared to its average volume of 1,448,084. Relay Therapeutics has a one year low of $5.60 and a one year high of $12.14. The stock has a market capitalization of $760.50 million, a price-to-earnings ratio of -2.27 and a beta of 1.64. The company's fifty day simple moving average is $6.93 and its two-hundred day simple moving average is $7.03.

Insider Transactions at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 6,802 shares of the business's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $6.06, for a total value of $41,220.12. Following the transaction, the chief financial officer now owns 306,391 shares in the company, valued at $1,856,729.46. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.32% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on RLAY shares. Jefferies Financial Group raised Relay Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the company from $10.60 to $16.00 in a report on Tuesday, September 10th. The Goldman Sachs Group assumed coverage on Relay Therapeutics in a report on Tuesday, September 10th. They set a "buy" rating and a $20.00 target price on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 target price on shares of Relay Therapeutics in a report on Tuesday, September 17th. JPMorgan Chase & Co. cut their target price on Relay Therapeutics from $23.00 to $21.00 and set an "overweight" rating on the stock in a report on Tuesday, September 10th. Finally, Barclays lifted their target price on Relay Therapeutics from $14.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, September 10th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Relay Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $21.11.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.